MRNS 2.83 +17%, that's why you do DD's...CBLI a strong commitment. : Yakov Kogan, Ph.D., MBA, Chief Executive Officer, stated, “The pursuit of approval by the EMA and FDA and commercialization for entolimod as a medical radiation countermeasure remains our top priority.” http://www.otcmarkets.com/edgar/GetFilingPdf?FilingID=12230538
"At June 30, 2017 , we had cash, cash equivalents and short-term investments of $11.5 million in the aggregate. Management believes this capital will fund the Company's operations and cash requirements for at least 12 months beyond the filing date of this Quarterly Report on Form 10-Q".
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.